From 6–9 May 2025, the Netherlands Embassy in Seoul, in collaboration with the Netherlands Enterprise Agency (RVO), is organising a trade mission to South Korea focused on the biotech sector. This is a unique opportunity for Dutch biotech companies to explore the South Korean market, attend the international BIO KOREA exhibition, and connect with Korean companies and stakeholders.
Companies can join a curated programme including access to the BIO KOREA trade fair, matchmaking sessions, company visits, and networking events. Eugene Kim, from the Netherlands Embassy in Seoul, is currently working on a strong programme tailored to Dutch biotech interests.
South Korea offers exciting opportunities for companies involved in innovation, drug development, and medical technologies. With growing demand and a well-established biotech infrastructure, it’s a market worth exploring.
There’s already strong interest from the Dutch business community, but a few spots are still available. Want to join and tap into South Korea’s biotech potential?
Check the full programme and register via the RVO website.
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.